Sugi Predict

Sugi Predict / Compounds / SCHEMBL15076451

SCHEMBL15076451

SCHEMBL15076451

CC(C)(C)OC(=O)N1CCC(O)C(CO[Si](C)(C)C(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ GLS O94925 3/20 0.38
▸ GPR119 Q8TDV5 3/20 0.38
▸ NR1H2 P55055 1/20 0.37
▸ FAAH O00519 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34468045 1.00 RECQL (0.40) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL30455847 0.90 NR1H2 (0.43) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL30661555 0.86 RECQL (0.40) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL31363042 0.86 RECQL (0.40) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL31153812 0.86 RECQL (0.40) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL3252633 0.84 RECQL (0.38) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL555796 0.84 ALDH1A1 (0.39) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL31153913 0.83 RECQL (0.38) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL15076452 0.83 RECQL (0.38) RECQLMEN1ALDH1A1MAPTKMT2A
SCHEMBL2902193 0.83 PDE4B (0.44) RECQLMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705293-A1 SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2026-03-11 — — EP disclosed
WO-2025059074-A1 BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2025-03-20 — — WO disclosed
WO-2024229317-A1 SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-11-07 — — WO disclosed
US-10722514-B2 Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof RAPT THERAPEUTICS, INC. (US) 2020-07-28 — — US disclosed
EP-3312160-B1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS INC (US) 2020-03-18 — — EP disclosed
US-20190142810-A1 MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS BASILEA PHARM INT AG (CH) 2019-05-16 — — US disclosed
US-20190142834-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2019-05-16 — — US disclosed
US-10246462-B2 Chemokine receptor modulators and uses thereof FLX BIO, INC. (US) 2019-04-02 — — US disclosed
US-10246462-B2 Chemokine receptor modulators and uses thereof FLX BIO, INC. (US) 2019-04-02 — — US disclosed
US-10233191-B2 Fused piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-03-19 — — US disclosed
US-9061008-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2015-06-23 — — US disclosed
US-9061008-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2015-06-23 — — US disclosed
US-20150152073-A1 Hepatitis B Antiviral Agents NOVIRA THERAPEUTICS, INC. 2015-06-04 — — US disclosed
WO-2015006280-A9 FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-14 — — WO disclosed
WO-2015006280-A1 FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-15 — — WO disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. 2014-06-26 — — US disclosed
US-8629274-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2014-01-14 — — US disclosed
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-09-26 — — US disclosed
WO-2013096744-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152073-A1 Hepatitis B Antiviral Agents HAVCR2, EIF2AK2, IRF3 RECQL 780/4885MEN1 4246/4885ALDH1A1 1564/4885
US-20190142834-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 RECQL 2655/4885MEN1 3693/4885ALDH1A1 3068/4885
US-10246462-B2 Chemokine receptor modulators and uses thereof ACKR3, CCR5, CXCR3 RECQL 4183/4885MEN1 4834/4885ALDH1A1 2109/4885
US-20140178337-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 RECQL 780/4885MEN1 4246/4885ALDH1A1 1564/4885
US-10233191-B2 Fused piperidine amides as modulators of ion channels TRPV1, TRPA1, KCNJ2 RECQL 2622/4885MEN1 4450/4885ALDH1A1 2307/4885
US-20190142810-A1 MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS NDUFAB1, FH, MT-ND1 RECQL 239/4885MEN1 1271/4885ALDH1A1 649/4885
US-10722514-B2 Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof USP7, SENP7, USP8 RECQL 2655/4885MEN1 3693/4885ALDH1A1 3068/4885
US-20130251673-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 RECQL 780/4885MEN1 4246/4885ALDH1A1 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.